A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer
X. Cynthia(Washington University in St. Louis), Paula M. Fracasso(University of Virginia)
Cited by 107
Related Papers
Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance)
|Journal of Clinical Oncology|2017|411
Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models
|Journal of Clinical Investigation|2012|222
Microscaled proteogenomic methods for precision oncology
|Nature Communications|2020|122
Functional Annotation of ESR1 Gene Fusions in Estrogen Receptor-Positive Breast Cancer
|Cell Reports|2018|110